<code id='8F45461716'></code><style id='8F45461716'></style>
    • <acronym id='8F45461716'></acronym>
      <center id='8F45461716'><center id='8F45461716'><tfoot id='8F45461716'></tfoot></center><abbr id='8F45461716'><dir id='8F45461716'><tfoot id='8F45461716'></tfoot><noframes id='8F45461716'>

    • <optgroup id='8F45461716'><strike id='8F45461716'><sup id='8F45461716'></sup></strike><code id='8F45461716'></code></optgroup>
        1. <b id='8F45461716'><label id='8F45461716'><select id='8F45461716'><dt id='8F45461716'><span id='8F45461716'></span></dt></select></label></b><u id='8F45461716'></u>
          <i id='8F45461716'><strike id='8F45461716'><tt id='8F45461716'><pre id='8F45461716'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:Wikipedia    Page View:1
          The FDA building -- First Opinion coverage from STAT
          Adobe

          WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

          Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

          advertisement

          To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          Change Healthcare cyberattack shows risk of industry consolidation
          Change Healthcare cyberattack shows risk of industry consolidation

          AdobeChangeHealthcare’srecentcyberattackhashospitals,doctors’offices,andpharmaciesacrossthecountryre

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Novo Nordisk to expand supply of Wegovy for U.S. patients

          BloombergphotobyGeorgeFreyLONDON—NovoNordisksaidWednesdaythatithadstartedtoincreasetheavailabilityof